Detalhe da pesquisa
1.
Model-informed dose selection for an investigational human epidermal growth factor receptor 2 antibody-drug conjugate FS-1502 in patients with human epidermal growth factor receptor 2-expressing advanced malignant solid tumours.
Br J Clin Pharmacol
; 90(4): 1115-1129, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37926561
2.
Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study.
Int J Clin Pract
; 2024: 1386980, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38481823
3.
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.
BMC Med
; 21(1): 230, 2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37400844
4.
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
Pulm Pharmacol Ther
; 73-74: 102132, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35595003
5.
Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.
Eur J Clin Pharmacol
; 78(9): 1421-1434, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35711066
6.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 374(17): 1621-34, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27119237
7.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Blood
; 130(5): 597-605, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550039
8.
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Future Oncol
; 14(11): 1035-1047, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268619
9.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Br J Haematol
; 174(5): 748-59, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27196567
10.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood
; 124(7): 1047-55, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24904120
11.
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Blood
; 124(7): 1038-46, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24920586
12.
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Invest New Drugs
; 34(3): 338-46, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27039387
13.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Invest New Drugs
; 33(3): 652-63, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25777468
14.
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Br J Clin Pharmacol
; 79(5): 789-800, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377318
15.
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Future Oncol
; 11(8): 1153-68, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25832873
16.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Lancet Oncol
; 15(13): 1503-1512, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456369
17.
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.
Cancer Cell
; 9(4): 287-300, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16616334
18.
Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
Adv Ther
; 40(3): 1074-1086, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627544
19.
Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.
Drugs R D
; 23(4): 465-473, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934354
20.
The Delivery of mRNA Vaccines for Therapeutics.
Life (Basel)
; 12(8)2022 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36013433